Fut, nem toboroz
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
LATAM LOWERS LDL-C
NCT06501443· 4. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
NCT05541341· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
NCT05445843· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822· 4. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746· 3. fázis· Novartis Pharmaceuticals· Forrás